Clinical Trials Logo

EGFR Mutation-Related Tumors clinical trials

View clinical trials related to EGFR Mutation-Related Tumors.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05498389 Not yet recruiting - Clinical trials for Stage IV Lung Cancer AJCC v8

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Start date: June 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the side effects and best dose of EMB-01 when given together with osimertinib in patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (advanced or metastatic) and has progressed on standard treatment. EMB-01 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth in this type of cancer. EMB-01 in combination with osimertinib may work better in treating patients with EGFR-mutant advanced non-small cell lung cancer.

NCT ID: NCT04304638 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Start date: March 2020
Phase:
Study type: Observational

The investigators will obtain a cohort of patients from multiple large cancer centers in China and try to unravel the efficacy of "radiotherapy combined with EGFR-TKI", which may provide some evidences for the treatment of stage III-inoperable NSCLC.